Nordhealth (OB:NORDH) Stock Faces Mounting Loss Pressure Despite Revenue Growth

Nordhealth stock closed at NOK23.40 on Wednesday after a choppy few months that left the 90 day return down about 14.6%. The headline from Q2 is not revenue, which reached €14.199 million. The focus is the ongoing profit squeeze, with the company posting a net loss of €3.635 million for the quarter and €15.908 million over the trailing twelve months.

Short term traders may fixate on the price swings. Long term investors will be asking how long Nordhealth can keep funding this level of losses while still pursuing its growth ambitions.

Is Nordhealth’s loss making profile simply too expensive at 3.2x P/S, or is the market underestimating the growth implied by that DCF gap? Compare the current share price to our valuation analysis for Nordhealth

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs. Q2 2025: €14.199 million vs. €12.861 million (higher quarterly revenue year on year)
• Net Loss, Q2 2026 vs. Q2 2025: €3.635 million loss vs. €2.932 million loss (loss widened year on year)
• Basic EPS, Q2 2026 vs. Q2 2025: Not disclosed for Q2 2026 vs. €0.03706 loss per share in Q2 2025 (the company continues to report a quarterly loss per share)
• Trailing 12-month Net Loss, Q2 2026 vs. Q2 2025: €15.908 million loss vs. €9.367 million loss (loss over the last 12 months increased relative to the prior 12-month period)

Prefer clear visuals instead of scrolling through line after line of financial figures? Get a full picture of Nordhealth’s balance sheet strength in an easy-to-scan chart format using our company report for Nordhealth.

Nordhealth earnings support longer term optimism

For a bullish lens, Nordhealth still fits the recurring software story investors often look for. Revenue for Q2 2026 is above Q2 2025, which supports the idea that clinics and practitioners are continuing to adopt or stick with its healthcare and veterinary platforms. Recent short term share price moves have been slightly positive over 7 and 30 days, which suggests the market has not treated this quarter as a clear setback, even as losses remain a key feature of the income statement.

Loss profile keeps pressure on Nordhealth

On the risk side, Nordhealth’s widening quarterly and trailing 12 month net loss works against any clean bullish story. The loss over the past year is materially larger than in the prior period, which points to ongoing pressure on the path toward break even. The 90 day share price performance is down about 14.6%, so recent trading still reflects concern about the cost of scaling this vertical SaaS healthcare model despite the underlying revenue growth.

After a 14.6% decline over 90 days and continued Nordhealth losses, are these setbacks isolated or early signs of deeper structural fragility? Review the risk analysis for Nordhealth which shows 2 important warning signs

Stay Ahead With Simply Wall St

If Nordhealth’s widening loss profile and recent 90 day share price decline have your attention, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and wait for a more attractive entry point. Once you hold the stock, use the Portfolio Command Center to cut through noise and focus on the most important updates on Nordhealth and your other positions. For a broader view, tap into thousands of investor views through the Community and see how others are weighing the same risks and opportunities. This is a simple way to surface hidden catalysts or early warning signs and stay one step ahead of the market.

Seeking Fresh Alternatives Beyond Nordhealth

Fresh ideas can move quickly. Some stocks are building quiet breakout momentum while others are dropping off the radar for now. Scan these under the radar setups and consider how they might fit your own strategy.

• Spot cash rich companies that could support their momentum with solid balance sheets by reviewing our curated list of solid balance sheet and fundamentals stocks (433 results) before the crowd catches on.
• Explore potential income and price momentum together by checking companies grouped as 445 dividend fortresses while yields and fundamentals still look aligned.
• Review candidates in the 56 AI infrastructure stocks to evaluate possible AI infrastructure opportunities while they are still off many radar screens.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com